Health · Pharma & Biotech · 5 hrs ago
Mitapivat Improves Hemoglobin but Not Pain Crisis Outcomes in Sickle Cell Trial
A phase III trial tested mitapivat in people with sickle cell disease.
Mitapivat, sold as Aqvesme, is a drug used for thalassemia.
The drug significantly improved hemoglobin response in the trial.
It did not outperform placebo in reducing pain crises.
This means the trial showed different results for its two main goals.
The findings were mixed, and the available information does not say what happens next.
Mitapivat significantly improved hemoglobin response in patients with sickle cell disease in a phase III trial.
The drug did not outperform placebo in reducing pain crises.
The trial aims to support further development of mitapivat for sickle cell disease.
The source identifies mitapivat as a thalassemia drug marketed as Aqvesme.
- Who
- Patients with sickle cell disease took part in the trial.
- What
- Mitapivat improved hemoglobin response but did not beat placebo at reducing pain crises.
- When
- Not stated
- Where
- Not stated
- Why
- The phase III trial aims to support further development of mitapivat for sickle cell disease.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Mitapivat (Aqvesme)
- Disease studied
- Sickle cell disease
- Trial phase
- Phase III
- Hemoglobin outcome
- Significantly improved response
- Pain crisis outcome
- Did not outperform placebo